Here's Why You Should Add STERIS (STE) Stock In Your Portfolio
Zacks Investment Research | Mar 01, 2020 08:48PM ET
STERIS plc (NYSE:STE) has been gaining from robust segmental growth. Expansions in both margins as well as the product and service portfolio along with increased fiscal 2020 guidance buoy optimism.
Over the past year, shares of the Zacks Rank #2 (Buy) company have outperformed its industry . The company has gained 31.2% against a 3.3% fall of its industry. Also, it has outperformed the S&P 500’s 7.1% rally during the same period.
The renowned provider of infection prevention and other procedural products and services has a market capitalization of $13.45 billion. The company projects 6.5% growth for the fourth quarter of fiscal 2020 and expects to maintain its strong segmental performance. Further, it delivered a positive earnings surprise of 5.8%, on average, in the trailing four quarters.
Let’s delve deeper.
Impressive Q3 Results: STERIS exited third-quarter fiscal 2020 with better-than-expected results. We are upbeat about the company’s solid revenue growth across each of its operating segments. Its year-over-year organic revenue growth at constant currency or CER in the fiscal third quarter was also impressive.
Contributions from elevated consumer demand, and a broader portfolio of products and services bode well for the company. Expansion of both margins during the quarter is also encouraging. In addition, increased fiscal 2020 guidance instills investors’ confidence in the stock.
Potential of Infection Prevention and Sterilization Wing: We are upbeat about STERIS’ continued benefits from the acquisition of the U.K.-based outsourced sterilization services provider, Synergy Health, as it paves the way for STERIS’ global leadership in infection prevention and sterilization. The sector recorded solid revenue growth from strong adoptions by the company’s global core medical device customer base.
The consolidation boosted STERIS' presence in the international markets as it combines the company’s strong presence in North America with Synergy's solid footprint across Europe. It also provided STERIS with an opportunity to better serve the emerging markets of the Asia Pacific and Latin America.
Healthcare and Pharmaceutical Industries Hold Potential: We are optimistic about the company’s growth potential in the healthcare and pharmaceutical industries. With life expectancy on the rise globally, a larger aging population increases the demand for medical procedures. This, in turn, translates into higher use of single-use medical devices and surgical kits processed by STERIS.
Get The News You Want
However, despite the upsides, the company’s stock price may witness a downturn due to several customers undergoing consolidation. This partly resulted from healthcare cost-reduction measures initiated by competitive pressures as well as legislators, regulators and third-party payors. The company also faces tough competition from biggies like Johnson & Johnson (NYSE:JNJ) as well as small companies. The continued efforts of the government and insurance companies to contain the rising cost of healthcare are also putting pressure on STERIS’ financial operations.
Estimate Trend
STERIS is witnessing a positive estimate revision trend for 2020. Over the past 30 days, the Zacks Consensus Estimate for its earnings has moved 0.6% north to $1.63.
The Zacks Consensus Estimate for the company’s fourth-quarter 2020 revenues is pegged at $807.5 million, suggesting a 5.1% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks from the broader medical space are ResMed Inc. (NYSE:RMD) , Medtronic plc (NYSE:MDT) and Hill-Rom Holdings, Inc. (NYSE:HRC) .
ResMed has a projected long-term earnings growth rate of 14.5%. It currently carries a Zacks Rank #2. You can see Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.